AurélienGredy

Associate

(T) 33.1.56.59.38.66

Aurélien Gredy practices in the area of general corporate and securities law, focusing on capital markets and public M&A deals. He advises companies and financial institutions on a wide array of capital markets transactions, including equity offerings, equity-linked and debt offerings, and IPOs.

Aurélien worked as an intern for major U.S. and French law firms, as well as in the equity capital markets team of one of the leading French investment banks, prior to joining Jones Day.

Experience

  • Voltalia completes €376 million capital increase with shareholders’ preferential subscription rightsJones Day represented Voltalia S.A. in connection with its €376 million offering by way of preferential subscription rights allocated to Voltalia's existing shareholders in a public offering in France and internationally in private placements to institutional investors.
  • Syndicate of leading banks complete €715 million share capital increase by Tikehau CapitalJones Day advised Berenberg, Credit Suisse, Natixis, BNP Paribas, Crédit Agricole Corporate and Investment Bank, and Société Générale, as global coordinators, joint lead managers and joint bookrunners, and Citigroup and RBC Capital Markets, as joint lead managers and joint bookrunners, in connection with the €715 million share capital increase without shareholders' preferential subscription rights and with a priority subscription period for existing shareholders by Tikehau Capital, an asset management and investment group.
  • APE obtains French constitutional Supreme Court approval for design of airport privatization planJones Day advised the Agence des Participations de l'Etat ("APE") on constitutional matters regarding the privatization of Aéroports de Paris ("ADP"), the French company managing the biggest airports around Paris (market value: €17 billion).
  • Stallergenes Greer plc acquired by Waypoint for approximately €110 million (US$124 million)Jones Day advised Stallergenes Greer plc in the recommended cash acquisition by Ares Life Sciences I S.à r.l. (Waypoint) of the entire issued, and to be issued, ordinary share capital of Stallergenes Greer not held directly or indirectly by Waypoint by way of a scheme of arrangement for approximately €110 million (US$124 million).
  • SVB Leerink, Barclays, Bryan Garnier, and Natixis underwrite $155.4 million Nasdaq IPO by GenfitJones Day acted as French counsel to the underwriters, led by SVB Leerink and Barclays, as global coordinators, and Bryan Garnier and Natixis, as European bookrunners, in connection with the initial public offering of Genfit S.A., a French Euronext Paris-listed biotechnology company on Nasdaq for a total aggregate amount of $155.4 million, after full exercise of the over-allotment option.
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.